Loading clinical trials...
Loading clinical trials...
An Open-label, Multi-center, Phase I-Ib/II Study of AUY922 Administered as Single Agent and in Combination With Bortezomib With or Without Dexamethasone in Adult Patients in Relapse or Refractory Multiple Myeloma.
Conditions
Interventions
AUY922
Bortezomib
+1 more
Locations
9
United States
Mayo Clinic - Arizona Cancer Clinical Research Unit
Scottsdale, Arizona, United States
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3)
San Antonio, Texas, United States
Novartis Investigative Site
Melbourne, Australia
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Würzburg, Germany
Start Date
July 1, 2008
Primary Completion Date
January 1, 2011
Completion Date
January 1, 2011
Last Updated
December 17, 2020
NCT07138209
NCT05913804
NCT06961669
NCT05503550
NCT05757973
NCT05011097
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions